The stratified win ratio

Journal of Biopharmaceutical Statistics

Volumn 28, Issue 4, 2018, Pages 778-796

  Dong, Gaohong ^a   Qiu, Junshan ^b   Wang, Duolao ^c   Vandemeulebroecke, Marc ^d  

^a iStats Inc   (United States)

^b CENTER FOR DRUG EVALUATION AND RESEARCH   (United States)

^c LIVERPOOL SCHOOL OF TROPICAL MEDICINE   (United Kingdom)

^d NOVARTIS PHARMA AG   (Switzerland)

Author keywords

composite endpoint; Mantel Haenszel stratified odds ratio; odds ratio; prioritized multiple outcomes; prioritized pairwise comparison; stratified win ratio; win ratio

Indexed keywords

ARTICLE; CONFIDENCE INTERVAL; HUMAN; MANTEL HAENSZEL TEST; NULL HYPOTHESIS; PRIORITY JOURNAL; RANDOMIZATION; SIMULATION; STATISTICAL PARAMETERS; WIN RATIO; BIOASSAY; COMPUTER SIMULATION; MONTE CARLO METHOD; ODDS RATIO; PROCEDURES; RANDOMIZED CONTROLLED TRIAL (TOPIC); SAMPLE SIZE; STATISTICAL ANALYSIS;

COMPUTER SIMULATION; DATA INTERPRETATION, STATISTICAL; ENDPOINT DETERMINATION; HUMANS; MONTE CARLO METHOD; ODDS RATIO; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SAMPLE SIZE;

EID: 85035109372     PISSN: 10543406     EISSN: 15205711     Source Type: Journal    
DOI: 10.1080/10543406.2017.1397007     Document Type: Article

References (40)

1. Abdalla, S., Montez-Rath, M. E., Parfrey, P. S., Chertow, G. M., (2016). The win ratio approach to analyzing composite outcomes: An application to the EVOLVE trial. Contemporary Clinical Trials 48:119–124.
2. Agresti, A., (2002). Categorical Data Analysis, 2nd. New York: John Wiley & Sons.
3. Agresti, A., (2013). Categorical Data Analysis, 3rd. New York: John Wiley & Sons.
4. Ariti, C. A., Cleland, J. G., Pocock, S. J., Pfeffer, M. A., Swedberg, K., Granger, C. B., McMurray, J. J., Michelson, E. L., Ostergren, J., Yusuf, S., (2011). Days alive and out of hospital and the patient journey in patients with heart failure: Insights from the candesartan in heart failure: Assessment of reduction in mortality and morbidity (CHARM) program. American Heart Journal 162(5):900–906.
5. Bakal, J. A., Roe, M. T., Ohman, E. M., Goodman, S. G., Fox, K. A., Zheng, Y., Westerhout, C. M., Hochman, J. S., Lokhnygina, Y., Brown, E. B., Armstrong, P. W., (2015a). Applying novel methods to assess clinical outcomes: Insights from the TRILOGY ACS trial. The European Heart Journal 36(6):385–392a.
6. Bakal, J. A., Westerhout, C. M., Armstrong, P. W., (2015b). Impact of weighted composite compared to traditional composite endpoints for the design of randomized controlled trials. Statistical Methods in Medical Research 24(6):980–988.
7. Bebu, I., Lachin, J. M., (2016). Large sample inference for a win ratio analysis of a composite outcome based on prioritized components. Biostatistics 17(1):178–187.
8. Breslow, N. E., Day, N. E., (1980). Statistical Methods in Cancer Research, Volume I: The Analysis of Case-Control Studies. Lyon, France: IARC Scientific Publications, No 32, International Agency for Research on Cancer.
9. Buyse, M., (2010). Generalized pairwise comparisons of prioritized outcomes in the two-sample problem. Statistics in Medicine 29(30):3245–3257.
10. Cochran, W. G., (1954). The combination of estimates from different experiments. Biometrics 10:101–129.
11. Cochran, W. G., (1983). Planning and Analysis of Observational Studies. Wiley: New York.
12. DerSimonian, R., Laird, N. M., (1986). Meta-analysis in clinical trials. Controlled Clinical Trials 7(3):177–188.
13. Dong, G., (2017). Meta-analysis for rare events as binary outcomes. In D., Chen, Z., Jin, G., Li, Y., Li, Y., Zhao (Eds.), New Advances in Statistics and Data Science. New York: Springer.
14. Dong, G., Li, D., Ballerstedt, S., Vandemeulebroecke, M., (2016). A generalized analytic solution to the win ratio to analyze a composite endpoint considering the clinical importance order among components. Pharmaceutical Statistics 15(5):430–437.
15. Dong, G., Guo, M., Hoaglin, C. D., Vandemeulebroecke, M., (2016a). Is the asymptotic variance estimator of the logarithm of the win ratio under the null hypothesis sound?–A note on the generalized analytic solution to the win ratio by Dong et al. (2016)”. Supporting information #7 (a post-publishing note) to Dong et al. (2016) (http://onlinelibrary.wiley.com/store/10.1002/pst.1763/asset/supinfo/pst1763-sup-0007-supplementary.pdf?v=1&s=cd757e23cb40556b3a1511b53c73747fe06fae89). Pharmaceutical Statistics 15(5):430–437.
16. Duc, A. N., Wolbers, M., (2017). Weighted analysis of composite endpoints with simultaneous inference for flexible weight constraints. Statistical Medica 36(3):442–454.
17. Gail, M. H., Wieand, W. Y., Piantadosi, S., (1984). Tests for no treatment effect in randomized clinical trials. Biometrika 75:57–64.
18. Henry, T. D., Schaer, G. L., DeMaria, A., Recker, D., Remmers, A. E., Goodrich, J., Patel, A., (2016). The iXCELL-DCM Trial: Rationale and design. Cell Transplantation 25(9):1689–1699.
19. Hoaglin, D. C., (2016). Misunderstandings about Q and ‘Cochran’s Q test’ in meta-analysis (with discussions). Statistics in Medicine 35(4):485–495.
20. Kulinskaya, E., Dollinger, M. B., (2015). An accurate test for homogeneity of odds ratios based on Cochran’s Q-statistic. BMC Medical Research Methodology 15:49.
21. Lachin, J., (2011). Biostatistical Methods: The Assessment of Relative Risks, 2nd. Hoboken, NJ: Wiley.
22. Luo, X., Tian, H., Mohanty, S., Tsai, W. Y., (2015). An alternative approach to confidence interval estimation for the win ratio statistic. Biometrics 71(1):139–145.
23. Luo, X., Qiu, J., Bai, S., Tian, H., (2017). Weighted win loss approach for analyzing prioritized outcomes. Statistics in Medicine 36(15):2452–2465.
24. Mantel, N., Haenszel, W., (1959). Statistical aspects of analysis of data from retrospective studies of disease. Journal of the National Cancer Institute 22:719–748.
25. Montgomery, A., Abuan, T., Kollef, M., (2014). The win ratio method: A novel hierarchical endpoint for pneumonia trials in patients on mechanical ventilation. 34th International Symposium on Intensive Care and Emergency Medicine, 18–21 March 2014, Brussels, Belgium.
26. Oakes, D., (2016). On the win-ratio statistic in clinical trials with multiple types of event. Biometrika 103(3):742–745.
27. Pfeffer, M. A., Swedberg, K., Granger, C. B., Held, P., McMurray, J. J. V., Michelson, E. L., Olofsson, B., Ostergren, J., Yusuf, S., for the CHARM Investigators and Committees. (2003). Effects of candesartan on mortality and morbidity in patients with chronic heart failure: The CHARM-Overall programme. Lancet 362:759–766.
28. Péron, J., Roy, P., Ozenne, B., Roche, L., Buyse, M., (2016). The net chance of a longer survival as a patient-oriented measure of treatment benefit in randomized clinical trials. JAMA Oncology 2(7):901–905.
29. Pocock, S. J., Ariti, C. A., Collier, T. J., Wang, D., (2012). The win ratio: A new approach to the analysis of composite endpoints in clinical trials based on clinical priorities. The European Heart Journal 33(2):176–182.
30. Pocock, S., Wang, D., Wilhelmsen, L., Hennekens, C. H., (2005). The data monitoring experience in the Candesartan in Heart Failure Assessment of Reduction in Mortality and morbidity (CHARM) program. American Heart Journal 149(5):939–943.
31. Prakash, R., Horsfall, M., Markwick, A., Pumar, M., Lee, L., Sinhal, A., Joseph, M. X., Chew, D. P., (2014). Prognostic impact of moderate or severe mitral regurgitation (MR) irrespective of concomitant comorbidities: A retrospective matched cohort study. BMJ Open 4(7):e004984.
32. Ramchandani, R., Schoenfeld, D. A., Finkelstein, D. M., (2016). Global rank tests for multiple, possibly censored, outcomes. Biometrics 72(3):926–935.
33. Robins, J. M., Breslow, N., Greenland, S., (1986). Estimators of Mantel-Haenszel variance consistent in both sparse data and large-Strata limiting models. Biometrics 42:311–323.
34. Rogers, J. K., Pocock, S. J., McMurray, J. J., Granger, C. B., Michelson, E. L., Östergren, J., Pfeffer, M. A., Solomon, S. D., Swedberg, K., Yusuf, S., (2014). Analysing recurrent hospitalizations in heart failure: A review of statistical methodology, with application to CHARM-Preserved. European Journal of Heart Failure 16(1):33–40.
35. Sampson, U. K., Metcalfe, C., Pfeffer, M. A., Solomon, S. D., Zou, K. H., (2010). Composite outcomes: Weighting component events according to severity assisted interpretation but reduced statistical power. Journal of Clinical Epidemiology 63:1156–1158.
36. Shuster, J. J., Guo, J. D., Skyler, J. S., (2012). Meta-analysis of safety for low event-rate binomial trials. Research Synthesis Methods 3(1):30–50.
37. Sutton, A., Abrams, K., Jones, D., Sheldon, T., Song, F., (2000). Methods for Meta-Analysis in Medical Research. West Sussex, England: Wiley.
38. Wang, D., Pocock, S., (2016). A win ratio approach to comparing continuous non-normal outcomes in clinical trials. Pharmaceutical Statistics 15(3):238–245.
39. Wei, L. J., Lin, D. Y., Weissfeld, L., (1989). Regression analysis of multivariate incomplete failure time data by modeling marginal distributions. Journal of the American Statistical Association 84:1064–1072.
40. Wei, L. J., Glidden, D. V., (1997). An overview of statistical methods for multiple failure time data in clinical trials. Statistics in Medicine 16(8):833–839.